- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Riverain Medical CAD product finds cancer, deletes bone
Bone can obscure lung lesions that may indicate cancer. The latest version of CAD software from Riverain Medical, shown publicly for the first time at RSNA 2010, takes care of the problem.
Bone can obscure lung lesions that may indicate cancer. The latest version of CAD software from Riverain Medical, shown publicly for the first time at RSNA 2010, takes care of the problem.
The newly available computer-assisted detection product automatically identifies and then draws markers around suspected lung cancer nodules on digital chest radiographs from which bone, such as ribs and the clavicle, have been subtracted.
The software is a hybrid of two Riverain products: CAD-based OnGuard 5.1 and the company’s bone-suppressing SoftView. As with both OnGuard and SoftView, the bundle works as an integral part of PACS, requiring no separate viewing station. It also works with all digital and computed radiography systems, according to Steve Worrell, chief technology officer at Riverain Medical.
In offering OnGuard, SoftView, and a blend of the two, Riverain provides enough choices to satisfy a range of needs, Worrell said. SoftView offers a bone-suppressed image of the chest. OnGuard 5.1 identifies and marks suspicious lesions for radiologists who simply want a CAD program. Together, they do it all.
Developing the two products separately, however, allowed the company to focus on improving the underlying capabilities of each. A fundamental weakness of CAD has been its tendency to impede rather than boost productivity. CAD typically is used as a “second read.” The algorithms insert markers indicating suspicious lesions after the primary read, forcing radiologists to go back over what they have already interpreted. Embedding bone suppression in OnGuard addresses this by making the primary read easier and, potentially, faster, according to Worrell.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the
Siemens Healthineers Debuts New Photon-Counting CT Systems at RSNA
December 2nd 2024Debuting at the Radiological Society of North American (RSNA) conference, the new photon-counting computed tomography (PPCT) scanners Naeotom Alpha.Pro and Naeotom Alpha.Prime reportedly combine rapid scan times with high-resolution precision.
